Myriad Genetics, Inc. (NASDAQ: MYGN) announced the commercial launch of its FirstGene Multiple Prenatal Screen, a lab test that runs four prenatal genetic screens simultaneously from a single blood draw, available as early as eight weeks gestation.

The test combines fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening into one integrated report. Results are expected to be delivered in approximately 10 days, according to the company's press release.

The fetal chromosome screen assesses risk for conditions including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), sex chromosome aneuploidies, and 22q11.2 microdeletion (DiGeorge syndrome). The fetal single-gene screen covers 19 recessive conditions and does not require a reproductive partner sample. The patient carrier screen covers 20 recessive conditions, including cystic fibrosis, spinal muscular atrophy, sickle cell disease, and fragile X syndrome. The fetal RhD screen assesses compatibility between patient and fetus.

Myriad states the screen has greater than 98% analytical sensitivity and greater than 99% analytical specificity, with analytical validation published in Clinical Chemistry in June 2026.

"One order. One draw. One report. Four simultaneous screens," said Brian Donnelly, Chief Commercial Officer of Myriad Genetics.